ClinicalTrials.gg
CompletedNCT03035032Updated Nov 26, 2024Results posted

A Study of ELIGARD® in Hormone-dependent Prostate Cancer Patients

A Phase 4 interventional study of Leuprolide in Prostate Cancer, sponsored by Astellas Pharma Singapore Pte. Ltd.. Completed at 19 sites in 8 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-26.

Sponsored by Astellas Pharma Singapore Pte. Ltd. (part of Astellas Pharma Inc) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
107
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies testing leuprolide in Prostatic Neoplasms — 9 open to participants now, 16 under way, 6 of them phase 3. Leuprolide · Prostatic Neoplasms.

Enrollment
28th of 69
107 · median 77
Started
2017
with 4 others
Phase 4
9 of 70
none open now
Registered
44th of 70
by date

Among the 70 studies testing leuprolide in Prostatic Neoplasms, this one is the 28th largest by enrollment of the 69 interventional ones that give a count, is one of 5 that started in 2017, is one of 9 in phase 4, and was the 44th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

9 of the 70 studies testing leuprolide in Prostatic Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About leuprolide

Leuprolide: first FDA approval 1985 (LUPRON), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing leuprolide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The objective of this study was to evaluate the safety profile of ELIGARD® in ethnic Asian prostate cancer patients.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Leuprolide acetate
  • Prostate cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A patient for whom the physician has decided to initiate treatment with a Luteinizing Hormone Releasing Hormone (LHRH) agonist in standard clinical practice
  • -proven prostate adenocarcinoma
  • Locally advanced prostate cancer with biochemical relapse radical prostatectomy and/or radiotherapy, OR hormonal treatment-naive advanced or prostate cancer patient who has not received chemotherapy and has no plans to undergo treatment with chemotherapy at study entry.
  • Patient who indicates that once the study is completed, he expects having access to androgen deprivation therapy (ADT), either medical or surgical, within the local healthcare system (either through public/ private health insurance or out of pocket payment).

Exclusion criteria

Exclusion Criteria:

  • Patient with castrate resistant prostate cancer
  • Patient who previously underwent bilateral orchiectomy
  • Patient who has received prior treatment with LHRH analogues
  • Prior or concomitant treatment with systemic chemotherapy. A patient where there is a likelihood to receive systemic chemotherapy should not be enrolled
  • of \< 1 year due to comorbidities
  • Participation in another interventional clinical trial within one month prior to study entry or during the duration of the study
  • Patient who plans to receive intermittent ADT at the time of study entry
  • Patient receiving non-palliative radiotherapy within 3 months prior to study entry
  • Patient receiving adjuvant ADT in combination with definitive radiotherapy
  • Patient with hormonal treatment-naive prostate cancer, for whom chemo-hormonal treatment (combination of Docetaxel and ADT) is indicated.
  • Patient with to gonadotropin releasing hormone (GnRH), GnRH agonist analogs or any of the components of ELIGARD®
  • Patient with any for ELIGARD® use based on local prescribing information
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
107 participants (actual)

Study arms

  • Experimental
    Leuprolide Acetate 22.5 milligrams (mg)

    Participants received 22.5 mg of leuprolide acetate (eligard) by subcutaneous injection at baseline, month 3, 6, 9, 12 and 15.

    Drug: Leuprolide

Interventions

  • Subcutaneous Injection

    Also known as: Eligard

06

What researchers measure

Primary outcomes

  1. Number of Participants With Eligard Related Adverse Events (AE)

    An AE was defined as any untoward medical occurrence in a participant administered a study drug or had undergone study procedures that did not necessarily have a causal relationship with this treatment. An AE was considered to be serious if, in the view of either the investigator or sponsor, it resulted in any of the following outcomes: resulted in death, was life-threatening, resulted in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, resulted in congenital anomaly or birth defect, required inpatient hospitalization or led to prolongation of hospitalization, other medically important events. Drug-related AEs are AEs where causal relationships were at least a reasonable possibility as determined by the investigator.

    Time frame: From first dose of study drug up to 18 months

Secondary outcomes

  1. Percentage of Participants With Testosterone Levels Less Than (<) 20, 20-50 and Greater Than (>) 50 Nanogram Per Deciliter (ng/dL) at Month 12

    Testosterone level was summarized based on the percentage of participants with \< 20 ng/dL, 20 to 50 ng/dL and \> 50 ng/dL.

    Time frame: Month 12

  2. Percentage of Participants With Testosterone Levels < 20, 20-50 and > 50 ng/dL at Month 18

    Testosterone level was summarized based on the percentage of participants with \< 20 ng/dL, 20 to 50 ng/dL and \> 50 ng/dL.

    Time frame: Month 18

  3. Time to PSA Progression

    Time to PSA progression was defined as (date of ≥25 percentage (%) increase and ≥ 2 ng/mL absolute increase) - (date of first administration of ELIGARD 22.5 mg)/30, where PSA progression was defiined as 25% or greater increase and an absolute increase of 2 ng/mL, and confirmed by a second value at least 3 weeks later. Participants with more than 1 qualifying PSA progression were counted only once, and the earlier progression was accounted for time to progression analysis.

    Time frame: From first dose of study drug up to PSA progression (18 months)

  4. Percentage of Participants With Greater Than or Equal to (≥) 30% PSA Percent Reduction From Baseline at Month 3, 6, 9, 12, 15, and 18

    PSA percent reduction (%) = (\[PSA tested- baseline PSA\]/baseline PSA)\*100%. PSA level was summarized based on time to PSA progression and PSA percent reduction by ≥ 30% with respect to the level at baseline. Participants with more than 1 qualifying PSA progression were counted only once, and the earlier progression was accounted for time to progression analysis. PSA progression was defined as 25% or greater increase and an absolute increase of 2 nanogram per milliliter (ng/mL), and confirmed by a second value at least 3 weeks later.

    Time frame: Months 3, 6, 9, 12, 15 and 18

  5. Percentage of Participants With ≥50% PSA Percent Reduction From Baseline at Month 3, 6, 9, 12, 15, and 18

    PSA percent reduction (%) = (\[PSA tested- baseline PSA\]/baseline PSA)\*100%. PSA level was summarized based on time to PSA progression and PSA percent reduction by ≥ 50% with respect to the level at baseline. Participants with more than 1 qualifying PSA progression were counted only once, and the earlier progression was accounted for time to progression analysis. PSA progression was defined as 25% or greater increase and an absolute increase of 2 ng/mL, and confirmed by a second value at least 3 weeks later.

    Time frame: Months 3, 6, 9, 12, 15 and 18

  6. Percentage of Participants With ≥90% PSA Percent Reduction From Baseline at Month 3, 6, 9, 12, 15, and 18

    PSA percent reduction (%) = (\[PSA tested- baseline PSA\]/baseline PSA)\*100%. PSA level was summarized based on time to PSA progression and PSA percent reduction by ≥ 90%, with respect to the level at baseline. Participants with more than 1 qualifying PSA progression were counted only once, and the earlier progression was accounted for time to progression analysis. PSA progression was defined as 25% or greater increase and an absolute increase of 2 ng/mL, and confirmed by a second value at least 3 weeks later.

    Time frame: Months 3, 6, 9, 12, 15 and 18

  7. Change From Baseline in EQ-5D-5L Health State Utility Index Score (Japan) at Months 6, 12 and 18

    EQ-5D-5L is a standardized instrument for use as a measure of health outcome and provides a simple descriptive profile and a single index value for health status. EQ-5D-5L is designed for self-completion by respondents and consists of 2 pages comprising the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension of the EQ-5D-5L has 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems) and the participant was asked to indicate his health state by ticking the box with the most appropriate statement. Index scores were generated using Japan value sets. Scores ranged from -0.111 to 1. Higher scores indicate better health state.

    Time frame: Baseline, months 6, 12 and 18

  8. Change From Baseline in EQ-5D-5L Health Status Utility Index Score (UK) at Months 6, 12 and 18

    EQ-5D-5L is a standardized instrument for use as a measure of health outcome and provides a simple descriptive profile and a single index value for health status. EQ-5D-5L is designed for self-completion by respondents and consists of 2 pages comprising the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension of the EQ-5D-5L has 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems) and the participant was asked to indicate his health state by ticking the box with the most appropriate statement. Index scores were generated using UK value sets. Scores ranged from -0.594 to 1. Higher scores indicate better health state.

    Time frame: Baseline, months 6, 12 and 18

  9. Change From Baseline in EQ-5D-5L Health Status Utility Index Score (US) at Months 6, 12 and 18

    EQ-5D-5L is a standardized instrument for use as a measure of health outcome and provides a simple descriptive profile and a single index value for health status. EQ-5D-5L is designed for self-completion by respondents and consists of 2 pages comprising the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension of the EQ-5D-5L has 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems) and the participants was asked to indicate his health state by ticking the box with the most appropriate statement. Index scores were generated using US value sets. Scores ranged from -0.109 to 1. Higher scores indicate better health state.

    Time frame: Baseline, months 6, 12 and 18

  10. Change From Baseline in EQ-5D02-EQ-VAS Score at Months 6, 12 and 18

    The EQ5D02-EQ-VAS is a vertical VAS with values between 0 (worst imaginable health) and 100 (best imaginable health), on which participants provide a global assessment of their health. Higher score indicate better health state.

    Time frame: Baseline, months 6, 12 and 18

  11. Change From Baseline in EORTC QLQ-PR25 Score at Months 6, 12 and 18

    EORTC QLQ-PR25 is a prostate cancer module for the assessment of health-related quality of life (HRQoL). EORTC QLQ-PR25 is designed for self-completion by respondents and assesses urinary symptoms, bowel symptoms, treatment-related symptoms and sexual activity and functioning. The rule of scoring for EORTC QLQ-PR25 follows instruction of EORTC QLQ-PR25 Scoring Manual 2.0. It consist of 25 questions distributed on 6 domains: urinary symptoms (8 items), incontinence aid (1 item), bowel symptoms (4 items), hormonal treatment-related symptoms (HTRS) (6 items), sexual activity (2 items), and sexual functioning (4 items). Questions used 4 point scale (1 'Not at all' to 4 'Very much'). All raw domain scores are linearly transformed to a 0-100 scale, with higher scores reflecting either more symptoms (urinary, bowel, hormonal treatment-related symptoms) or higher levels of activity or functioning (sexual).

    Time frame: Baseline, months 6, 12 and 18

07

Results

Posted Dec 9, 2020

Participant flow

Asian male participants above the age of 18 years with biopsy-proven prostate adenocarcinoma who fulfill the eligibility criteria were enrolled in this study.

Participant flow — Overall Study
MilestoneLeuprolide Acetate 22.5 Milligrams (mg)
Started107
Completed64
Not completed43
Withdrew: Adverse event2
Withdrew: Death9
Withdrew: Lost to follow-up1
Withdrew: Progressive disease22
Withdrew: Protocol violation2
Withdrew: Withdrawal by subject2
Withdrew: Physician decision5

Outcome measures

PrimaryNumber of Participants With Eligard Related Adverse Events (AE)

An AE was defined as any untoward medical occurrence in a participant administered a study drug or had undergone study procedures that did not necessarily have a causal relationship with this treatment. An AE was considered to be serious if, in the view of either the investigator or sponsor, it resulted in any of the following outcomes: resulted in death, was life-threatening, resulted in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, resulted in congenital anomaly or birth defect, required inpatient hospitalization or led to prolongation of hospitalization, other medically important events. Drug-related AEs are AEs where causal relationships were at least a reasonable possibility as determined by the investigator.

Time frame:
From first dose of study drug up to 18 months
Reported as:
Number · Participants
Number of Participants With Eligard Related Adverse Events (AE)
ParticipantsLeuprolide Acetate 22.5 mg
Drug-related adverse event15
Drug-related serious adverse event2
SecondaryPercentage of Participants With Testosterone Levels Less Than (<) 20, 20-50 and Greater Than (>) 50 Nanogram Per Deciliter (ng/dL) at Month 12

Testosterone level was summarized based on the percentage of participants with \< 20 ng/dL, 20 to 50 ng/dL and \> 50 ng/dL.

Time frame:
Month 12
Reported as:
Number · Percentage of participants
Percentage of Participants With Testosterone Levels Less Than (<) 20, 20-50 and Greater Than (>) 50 Nanogram Per Deciliter (ng/dL) at Month 12
Percentage of participantsLeuprolide Acetate 22.5 mg
< 20 ng/dL51.4
20 - 50 ng/dL12.4
> 50 ng/dL1.9
SecondaryPercentage of Participants With Testosterone Levels < 20, 20-50 and > 50 ng/dL at Month 18

Testosterone level was summarized based on the percentage of participants with \< 20 ng/dL, 20 to 50 ng/dL and \> 50 ng/dL.

Time frame:
Month 18
Reported as:
Number · Percentage of participants
Percentage of Participants With Testosterone Levels < 20, 20-50 and > 50 ng/dL at Month 18
Percentage of participantsLeuprolide Acetate 22.5 mg
< 20 ng/dL61.9
20 - 50 ng/dL16.2
> 50 ng/dL1.9
SecondaryTime to PSA Progression

Time to PSA progression was defined as (date of ≥25 percentage (%) increase and ≥ 2 ng/mL absolute increase) - (date of first administration of ELIGARD 22.5 mg)/30, where PSA progression was defiined as 25% or greater increase and an absolute increase of 2 ng/mL, and confirmed by a second value at least 3 weeks later. Participants with more than 1 qualifying PSA progression were counted only once, and the earlier progression was accounted for time to progression analysis.

Time frame:
From first dose of study drug up to PSA progression (18 months)
Reported as:
Median · Months
Time to PSA Progression
MonthsLeuprolide Acetate 22.5 mg
Time to PSA Progression8.80 (6.10 to 9.20)
SecondaryPercentage of Participants With Greater Than or Equal to (≥) 30% PSA Percent Reduction From Baseline at Month 3, 6, 9, 12, 15, and 18

PSA percent reduction (%) = (\[PSA tested- baseline PSA\]/baseline PSA)\*100%. PSA level was summarized based on time to PSA progression and PSA percent reduction by ≥ 30% with respect to the level at baseline. Participants with more than 1 qualifying PSA progression were counted only once, and the earlier progression was accounted for time to progression analysis. PSA progression was defined as 25% or greater increase and an absolute increase of 2 nanogram per milliliter (ng/mL), and confirmed by a second value at least 3 weeks later.

Time frame:
Months 3, 6, 9, 12, 15 and 18
Reported as:
Number · Percentage of participants
Percentage of Participants With Greater Than or Equal to (≥) 30% PSA Percent Reduction From Baseline at Month 3, 6, 9, 12, 15, and 18
Percentage of participantsLeuprolide Acetate 22.5 mg
Month 396.1
Month 693.8
Month 992.8
Month 1297.1
Month 1598.4
Month 1891.0
SecondaryPercentage of Participants With ≥50% PSA Percent Reduction From Baseline at Month 3, 6, 9, 12, 15, and 18

PSA percent reduction (%) = (\[PSA tested- baseline PSA\]/baseline PSA)\*100%. PSA level was summarized based on time to PSA progression and PSA percent reduction by ≥ 50% with respect to the level at baseline. Participants with more than 1 qualifying PSA progression were counted only once, and the earlier progression was accounted for time to progression analysis. PSA progression was defined as 25% or greater increase and an absolute increase of 2 ng/mL, and confirmed by a second value at least 3 weeks later.

Time frame:
Months 3, 6, 9, 12, 15 and 18
Reported as:
Number · Percentage of participants
Percentage of Participants With ≥50% PSA Percent Reduction From Baseline at Month 3, 6, 9, 12, 15, and 18
Percentage of participantsLeuprolide Acetate 22.5 mg
Month 389.2
Month 691.7
Month 991.6
Month 1294.2
Month 1596.9
Month 1888.8
SecondaryPercentage of Participants With ≥90% PSA Percent Reduction From Baseline at Month 3, 6, 9, 12, 15, and 18

PSA percent reduction (%) = (\[PSA tested- baseline PSA\]/baseline PSA)\*100%. PSA level was summarized based on time to PSA progression and PSA percent reduction by ≥ 90%, with respect to the level at baseline. Participants with more than 1 qualifying PSA progression were counted only once, and the earlier progression was accounted for time to progression analysis. PSA progression was defined as 25% or greater increase and an absolute increase of 2 ng/mL, and confirmed by a second value at least 3 weeks later.

Time frame:
Months 3, 6, 9, 12, 15 and 18
Reported as:
Number · Percentage of participants
Percentage of Participants With ≥90% PSA Percent Reduction From Baseline at Month 3, 6, 9, 12, 15, and 18
Percentage of participantsLeuprolide Acetate 22.5 mg
Month 369.6
Month 677.1
Month 977.1
Month 1281.2
Month 1579.7
Month 1868.5
SecondaryChange From Baseline in EQ-5D-5L Health State Utility Index Score (Japan) at Months 6, 12 and 18

EQ-5D-5L is a standardized instrument for use as a measure of health outcome and provides a simple descriptive profile and a single index value for health status. EQ-5D-5L is designed for self-completion by respondents and consists of 2 pages comprising the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension of the EQ-5D-5L has 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems) and the participant was asked to indicate his health state by ticking the box with the most appropriate statement. Index scores were generated using Japan value sets. Scores ranged from -0.111 to 1. Higher scores indicate better health state.

Time frame:
Baseline, months 6, 12 and 18
Reported as:
Mean · Score on a scale
Change From Baseline in EQ-5D-5L Health State Utility Index Score (Japan) at Months 6, 12 and 18
Score on a scaleLeuprolide Acetate 22.5 mg
Month 6-0.0047 ± 0.16874
Month 12-0.0093 ± 0.14456
Month 18-0.0262 ± 0.17520
SecondaryChange From Baseline in EQ-5D-5L Health Status Utility Index Score (UK) at Months 6, 12 and 18

EQ-5D-5L is a standardized instrument for use as a measure of health outcome and provides a simple descriptive profile and a single index value for health status. EQ-5D-5L is designed for self-completion by respondents and consists of 2 pages comprising the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension of the EQ-5D-5L has 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems) and the participant was asked to indicate his health state by ticking the box with the most appropriate statement. Index scores were generated using UK value sets. Scores ranged from -0.594 to 1. Higher scores indicate better health state.

Time frame:
Baseline, months 6, 12 and 18
Reported as:
Mean · Score on a scale
Change From Baseline in EQ-5D-5L Health Status Utility Index Score (UK) at Months 6, 12 and 18
Score on a scaleLeuprolide Acetate 22.5 mg
Month 60.0055 ± 0.21662
Month 9-0.0051 ± 0.16493
Month 18-0.0259 ± 0.23831
SecondaryChange From Baseline in EQ-5D-5L Health Status Utility Index Score (US) at Months 6, 12 and 18

EQ-5D-5L is a standardized instrument for use as a measure of health outcome and provides a simple descriptive profile and a single index value for health status. EQ-5D-5L is designed for self-completion by respondents and consists of 2 pages comprising the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension of the EQ-5D-5L has 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems) and the participants was asked to indicate his health state by ticking the box with the most appropriate statement. Index scores were generated using US value sets. Scores ranged from -0.109 to 1. Higher scores indicate better health state.

Time frame:
Baseline, months 6, 12 and 18
Reported as:
Mean · Score on a scale
Change From Baseline in EQ-5D-5L Health Status Utility Index Score (US) at Months 6, 12 and 18
Score on a scaleLeuprolide Acetate 22.5 mg
Month 60.0017 ± 0.15819
Month 9-0.0047 ± 0.12477
Month 18-0.0191 ± 0.16934
SecondaryChange From Baseline in EQ-5D02-EQ-VAS Score at Months 6, 12 and 18

The EQ5D02-EQ-VAS is a vertical VAS with values between 0 (worst imaginable health) and 100 (best imaginable health), on which participants provide a global assessment of their health. Higher score indicate better health state.

Time frame:
Baseline, months 6, 12 and 18
Reported as:
Mean · Score on a scale
Change From Baseline in EQ-5D02-EQ-VAS Score at Months 6, 12 and 18
Score on a scaleLeuprolide Acetate 22.5 mg
Month 61.3 ± 14.72
Month 92.1 ± 11.92
Month 182.0 ± 15.65
SecondaryChange From Baseline in EORTC QLQ-PR25 Score at Months 6, 12 and 18

EORTC QLQ-PR25 is a prostate cancer module for the assessment of health-related quality of life (HRQoL). EORTC QLQ-PR25 is designed for self-completion by respondents and assesses urinary symptoms, bowel symptoms, treatment-related symptoms and sexual activity and functioning. The rule of scoring for EORTC QLQ-PR25 follows instruction of EORTC QLQ-PR25 Scoring Manual 2.0. It consist of 25 questions distributed on 6 domains: urinary symptoms (8 items), incontinence aid (1 item), bowel symptoms (4 items), hormonal treatment-related symptoms (HTRS) (6 items), sexual activity (2 items), and sexual functioning (4 items). Questions used 4 point scale (1 'Not at all' to 4 'Very much'). All raw domain scores are linearly transformed to a 0-100 scale, with higher scores reflecting either more symptoms (urinary, bowel, hormonal treatment-related symptoms) or higher levels of activity or functioning (sexual).

Time frame:
Baseline, months 6, 12 and 18
Reported as:
Mean · Score on a scale
Change From Baseline in EORTC QLQ-PR25 Score at Months 6, 12 and 18
Score on a scaleLeuprolide Acetate 22.5 mg
Week 6: Urinary Symptoms-4.84 ± 15.669
Week 6: Incontinence Aid-5.21 ± 28.220
Week 6: Bowel Symptoms-2.17 ± 8.311
Week 6: HTRS3.27 ± 11.008
Week 6: Sexually Active-6.08 ± 17.290
Week 6: Sexual Function-1.44 ± 11.362
Week 12: Urinary Symptoms-6.93 ± 15.237
Week 12: Incontinence Aid-11.11 ± 32.338
Week 12: Bowel Symptoms-2.66 ± 9.533
Week 12: HTRS2.14 ± 9.959
Week 12: Sexually Active-5.07 ± 16.983
Week 12: Sexual Function-2.99 ± 14.823
Week 18: Urinary Symptoms-4.06 ± 15.370
Week 18: Incontinence Aid1.67 ± 31.484
Week 18: Bowel Symptoms0.31 ± 9.036
Week 18: HTRS4.68 ± 11.064
Week 18: Sexually Active-3.54 ± 23.334
Week 18: Sexual Function-8.52 ± 15.969

Adverse events

Collected over From first dose of study drug up to 18 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Leuprolide Acetate 22.5 mg9/106 (8.5%)31/106 (29.2%)42/106 (39.6%)
Most frequent serious events
Showing 10 of 43
Most frequent serious events
EventLeuprolide Acetate 22.5 mg
PneumoniaInfections and infestations4/106
DeathGeneral disorders3/106
AnaemiaBlood and lymphatic system disorders2/106
ArthralgiaMusculoskeletal and connective tissue disorders2/106
Back painMusculoskeletal and connective tissue disorders2/106
Haemorrhage intracranialNervous system disorders2/106
NeuralgiaNervous system disorders2/106
Cardiac failure congestiveCardiac disorders1/106
Abdominal wall haematomaGastrointestinal disorders1/106
Anal hypoaesthesiaGastrointestinal disorders1/106
Most frequent other events
Most frequent other events
EventLeuprolide Acetate 22.5 mg
Prostatic specific antigen increasedInvestigations18/106
CoughRespiratory, thoracic and mediastinal disorders10/106
Back painMusculoskeletal and connective tissue disorders8/106
Hot flushVascular disorders8/106
AnaemiaBlood and lymphatic system disorders6/106
Upper respiratory tract infectionInfections and infestations6/106

Baseline characteristics

Safety Analysis Set (SAF) :The SAF consisted of all participants who received at least 1 eligard injection and any follow-up safety information was available.

Age, Continuous
Age, Continuous(Years)Leuprolide Acetate 22.5 Milligrams (mg)
Mean72.2 ± 7.43
Sex: Female, Male
Sex: Female, Male(Participants)Leuprolide Acetate 22.5 Milligrams (mg)
Female0
Male106
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Leuprolide Acetate 22.5 Milligrams (mg)
Hispanic or Latino0
Not Hispanic or Latino0
Unknown or Not Reported106
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Leuprolide Acetate 22.5 Milligrams (mg)
American Indian or Alaska Native0
Asian106
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Prostate-specific antigen (PSA) Level at Initial Diagnosis
Prostate-specific antigen (PSA) Level at Initial Diagnosis(Nanogram per milliliter (ng/mL))Leuprolide Acetate 22.5 Milligrams (mg)
Mean315.05 ± 989.552
EuroQol-5 Dimension-5 Level (EQ-5D-5L) Health State Utility Index Score (Japan)
EuroQol-5 Dimension-5 Level (EQ-5D-5L) Health State Utility Index Score (Japan)(Score on a scale)Leuprolide Acetate 22.5 Milligrams (mg)
Mean0.8162 ± 0.18916
EQ-5D-5L Index Score (UK)
EQ-5D-5L Index Score (UK)(Score on a scale)Leuprolide Acetate 22.5 Milligrams (mg)
Mean0.8040 ± 0.25853
EQ-5D-5L Index Score (US)
EQ-5D-5L Index Score (US)(Score on a scale)Leuprolide Acetate 22.5 Milligrams (mg)
Mean0.8503 ± 0.18360

2 further baseline measures are reported on the registry.

08

Study locations

19 sites
  • Site HK01001
    Hong Kong, Hong Kong
  • Site HK01002
    Hong Kong, Hong Kong
  • Site ID02001
    Jakarta, DKI Jakarta, Indonesia
  • Site MY03002
    Batu Caves, Selangor, Malaysia
  • Site MY03001
    Kuala Lumpur, Malaysia
  • Site PH04001
    Makati City, Metro Manila, Philippines
  • Site PH04003
    Manila, Metro Manila, Philippines
  • Site PH04002
    San Juan, Metro Manila, Philippines
  • Site SG05001
    Singapore, Singapore
  • Site SG05002
    Singapore, Singapore
  • Site SG05003
    Singapore, Singapore
  • Site TW06001
    Taichung, Taiwan
  • Site TW06002
    Taichung, Taiwan
  • Site TW06003
    Taipei, Taiwan
  • Site TH07001
    Muang, Chiang Mai, Thailand
  • Site TH07004
    Hat Yai, Songkhla, Thailand
  • Site TH07003
    Bangkok, Thailand
  • Site VN08001
    Ho Chi Minh City, Vietnam
  • Site VN08002
    Ho Chi Minh City, Vietnam
09

References and documents

Publications

  • Malek R, Wu ST, Serrano D, Tho T, Umbas R, Teoh J, Lojanapiwat B, Ong TA, On WK, Thai SM, Kim J, Pophale R, Chiong E. ELIGANT: a Phase 4, interventional, safety study of leuprorelin acetate (ELIGARD(R)) in Asian men with prostate cancer. Transl Androl Urol. 2022 Feb;11(2):179-189. doi: 10.21037/tau-21-723. PubMed 35280654 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

Data sharing details ↗ · www.clinicaltrials.astellas.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2017 to primary completion in Nov 2019, 28 months.

Results were first posted in Dec 2020, 1 year after primary completion.

Of 52 phase 4 interventional studies under Prostatic Neoplasms, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 67. This study's 28 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2017
First posted
Jan 27, 2017
StartActual
Jun 23, 2017
Primary completionActual
Nov 19, 2019
CompletionActual
Nov 19, 2019
Results first posted
Dec 9, 2020
Last update
Nov 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03035032
Responsible party
Sponsor
First posted
Jan 27, 2017
Start date
Jun 23, 2017
Primary completion
Nov 19, 2019
Completion
Nov 19, 2019
Results posted
Dec 9, 2020
Last update
Nov 26, 2024

Study contacts

Medical Director
study director · Astellas Pharma Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leuprolide

Start the discussion